Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase

Janelle Y. Saulter, Joseph R. Kurian, Lauren A. Trepanier, Richard R. Tidwell, Arlene S. Bridges, David W. Boykin, Chad E. Stephens, Mariappan Anbazhagan, James Edwin Hall

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Furamidine is an effective antimicrobial agent; however, oral potency of furamidine is poor. A prodrug of furamidine, 2,5-bis(4-amidinophenyl)furan-bis- O-methylamidoxime (DB289), has greatly improved oral potency. DB289 is transformed to furamidine via O-demethylation, and N-dehydroxylation reactions with four intermediate metabolites formed. The O-demethylation reactions have been shown to be catalyzed by cytochrome P450. The enzymes catalyzing the reductive N-dehydroxylation reactions have not been determined. The objective of this study was to identify the enzymes that catalyze N-dehydroxylation of metabolites M1, a monoamidoxime, and M2, a diamidoxime, formed during generation of furamidine. M1 and M2 metabolism was investigated using human liver microsomes and human soluble cytochrome b5 and NAD cytochrome b 5 reductase, expressed in Escherichia coli. Kinetics of M1 and M2 reduction by human liver microsomes exhibited high affinity and moderate capacity. Metabolism was significantly inhibited by antibodies to cytochrome b5 and b5 reductase and by chemical inhibitors of b 5 reductase. The amidoximes were efficiently metabolized by liver mitochondria, which contain cytochrome b5/b5 reductase, but not by liver cytosol, which contains minimal amounts of these proteins. Expressed cytochrome b5/b5 reductase, in the absence of any other proteins, efficiently catalyzed reduction of both amidoximes. K m values were similar to those for microsomes, and Vmax values were 33- to 36-fold higher in the recombinant system compared with microsomes. Minimal activity was seen with cytochrome b5 or b 5 reductase alone or with cytochrome P450 reductase alone or with cytochrome b5. These results indicate that cytochrome b5 and b5 reductase play a direct role in metabolic activation of DB289 to furamidine.

Original languageEnglish (US)
Pages (from-to)1886-1893
Number of pages8
JournalDrug Metabolism and Disposition
Volume33
Issue number12
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Cytochrome-B(5) Reductase
Cytochromes b5
Prodrugs
Oxidoreductases
Liver Microsomes
Microsomes
NADPH-Ferrihemoprotein Reductase
Cytochromes b
amidoxime
Liver Mitochondrion
Enzymes
Anti-Infective Agents
NAD
Cytosol
Cytochrome P-450 Enzyme System
furamidine
Proteins
Escherichia coli

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Saulter, J. Y., Kurian, J. R., Trepanier, L. A., Tidwell, R. R., Bridges, A. S., Boykin, D. W., ... Hall, J. E. (2005). Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metabolism and Disposition, 33(12), 1886-1893. https://doi.org/10.1124/dmd.105.005017

Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. / Saulter, Janelle Y.; Kurian, Joseph R.; Trepanier, Lauren A.; Tidwell, Richard R.; Bridges, Arlene S.; Boykin, David W.; Stephens, Chad E.; Anbazhagan, Mariappan; Hall, James Edwin.

In: Drug Metabolism and Disposition, Vol. 33, No. 12, 01.12.2005, p. 1886-1893.

Research output: Contribution to journalArticle

Saulter, JY, Kurian, JR, Trepanier, LA, Tidwell, RR, Bridges, AS, Boykin, DW, Stephens, CE, Anbazhagan, M & Hall, JE 2005, 'Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase', Drug Metabolism and Disposition, vol. 33, no. 12, pp. 1886-1893. https://doi.org/10.1124/dmd.105.005017
Saulter, Janelle Y. ; Kurian, Joseph R. ; Trepanier, Lauren A. ; Tidwell, Richard R. ; Bridges, Arlene S. ; Boykin, David W. ; Stephens, Chad E. ; Anbazhagan, Mariappan ; Hall, James Edwin. / Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. In: Drug Metabolism and Disposition. 2005 ; Vol. 33, No. 12. pp. 1886-1893.
@article{1d34fd8441904b8e8d0aeb038a32c355,
title = "Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase",
abstract = "Furamidine is an effective antimicrobial agent; however, oral potency of furamidine is poor. A prodrug of furamidine, 2,5-bis(4-amidinophenyl)furan-bis- O-methylamidoxime (DB289), has greatly improved oral potency. DB289 is transformed to furamidine via O-demethylation, and N-dehydroxylation reactions with four intermediate metabolites formed. The O-demethylation reactions have been shown to be catalyzed by cytochrome P450. The enzymes catalyzing the reductive N-dehydroxylation reactions have not been determined. The objective of this study was to identify the enzymes that catalyze N-dehydroxylation of metabolites M1, a monoamidoxime, and M2, a diamidoxime, formed during generation of furamidine. M1 and M2 metabolism was investigated using human liver microsomes and human soluble cytochrome b5 and NAD cytochrome b 5 reductase, expressed in Escherichia coli. Kinetics of M1 and M2 reduction by human liver microsomes exhibited high affinity and moderate capacity. Metabolism was significantly inhibited by antibodies to cytochrome b5 and b5 reductase and by chemical inhibitors of b 5 reductase. The amidoximes were efficiently metabolized by liver mitochondria, which contain cytochrome b5/b5 reductase, but not by liver cytosol, which contains minimal amounts of these proteins. Expressed cytochrome b5/b5 reductase, in the absence of any other proteins, efficiently catalyzed reduction of both amidoximes. K m values were similar to those for microsomes, and Vmax values were 33- to 36-fold higher in the recombinant system compared with microsomes. Minimal activity was seen with cytochrome b5 or b 5 reductase alone or with cytochrome P450 reductase alone or with cytochrome b5. These results indicate that cytochrome b5 and b5 reductase play a direct role in metabolic activation of DB289 to furamidine.",
author = "Saulter, {Janelle Y.} and Kurian, {Joseph R.} and Trepanier, {Lauren A.} and Tidwell, {Richard R.} and Bridges, {Arlene S.} and Boykin, {David W.} and Stephens, {Chad E.} and Mariappan Anbazhagan and Hall, {James Edwin}",
year = "2005",
month = "12",
day = "1",
doi = "10.1124/dmd.105.005017",
language = "English (US)",
volume = "33",
pages = "1886--1893",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "12",

}

TY - JOUR

T1 - Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase

AU - Saulter, Janelle Y.

AU - Kurian, Joseph R.

AU - Trepanier, Lauren A.

AU - Tidwell, Richard R.

AU - Bridges, Arlene S.

AU - Boykin, David W.

AU - Stephens, Chad E.

AU - Anbazhagan, Mariappan

AU - Hall, James Edwin

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Furamidine is an effective antimicrobial agent; however, oral potency of furamidine is poor. A prodrug of furamidine, 2,5-bis(4-amidinophenyl)furan-bis- O-methylamidoxime (DB289), has greatly improved oral potency. DB289 is transformed to furamidine via O-demethylation, and N-dehydroxylation reactions with four intermediate metabolites formed. The O-demethylation reactions have been shown to be catalyzed by cytochrome P450. The enzymes catalyzing the reductive N-dehydroxylation reactions have not been determined. The objective of this study was to identify the enzymes that catalyze N-dehydroxylation of metabolites M1, a monoamidoxime, and M2, a diamidoxime, formed during generation of furamidine. M1 and M2 metabolism was investigated using human liver microsomes and human soluble cytochrome b5 and NAD cytochrome b 5 reductase, expressed in Escherichia coli. Kinetics of M1 and M2 reduction by human liver microsomes exhibited high affinity and moderate capacity. Metabolism was significantly inhibited by antibodies to cytochrome b5 and b5 reductase and by chemical inhibitors of b 5 reductase. The amidoximes were efficiently metabolized by liver mitochondria, which contain cytochrome b5/b5 reductase, but not by liver cytosol, which contains minimal amounts of these proteins. Expressed cytochrome b5/b5 reductase, in the absence of any other proteins, efficiently catalyzed reduction of both amidoximes. K m values were similar to those for microsomes, and Vmax values were 33- to 36-fold higher in the recombinant system compared with microsomes. Minimal activity was seen with cytochrome b5 or b 5 reductase alone or with cytochrome P450 reductase alone or with cytochrome b5. These results indicate that cytochrome b5 and b5 reductase play a direct role in metabolic activation of DB289 to furamidine.

AB - Furamidine is an effective antimicrobial agent; however, oral potency of furamidine is poor. A prodrug of furamidine, 2,5-bis(4-amidinophenyl)furan-bis- O-methylamidoxime (DB289), has greatly improved oral potency. DB289 is transformed to furamidine via O-demethylation, and N-dehydroxylation reactions with four intermediate metabolites formed. The O-demethylation reactions have been shown to be catalyzed by cytochrome P450. The enzymes catalyzing the reductive N-dehydroxylation reactions have not been determined. The objective of this study was to identify the enzymes that catalyze N-dehydroxylation of metabolites M1, a monoamidoxime, and M2, a diamidoxime, formed during generation of furamidine. M1 and M2 metabolism was investigated using human liver microsomes and human soluble cytochrome b5 and NAD cytochrome b 5 reductase, expressed in Escherichia coli. Kinetics of M1 and M2 reduction by human liver microsomes exhibited high affinity and moderate capacity. Metabolism was significantly inhibited by antibodies to cytochrome b5 and b5 reductase and by chemical inhibitors of b 5 reductase. The amidoximes were efficiently metabolized by liver mitochondria, which contain cytochrome b5/b5 reductase, but not by liver cytosol, which contains minimal amounts of these proteins. Expressed cytochrome b5/b5 reductase, in the absence of any other proteins, efficiently catalyzed reduction of both amidoximes. K m values were similar to those for microsomes, and Vmax values were 33- to 36-fold higher in the recombinant system compared with microsomes. Minimal activity was seen with cytochrome b5 or b 5 reductase alone or with cytochrome P450 reductase alone or with cytochrome b5. These results indicate that cytochrome b5 and b5 reductase play a direct role in metabolic activation of DB289 to furamidine.

UR - http://www.scopus.com/inward/record.url?scp=28144457470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28144457470&partnerID=8YFLogxK

U2 - 10.1124/dmd.105.005017

DO - 10.1124/dmd.105.005017

M3 - Article

VL - 33

SP - 1886

EP - 1893

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 12

ER -